Hunan Provincal Tumor Hospital Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2017
NCT03198923
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hunan Provincal Tumor Hospital | Hunan Provincial Tumor Hospital | Wenxiang Wang | Xianhai Mao

Active Ingredients

Drugs in Phase 2 Trials (3)

anlotinib (1 trial)

neoantigen dna vaccine (1 trial)

tq-b2450 (1 trial)

Drugs in Phase 1 Trials (3)

allogeneic natural killer cells (1 trial)

osimertinib (tagrisso) (1 trial)

ty-9591 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6